Funds Canadian research on how veterinary and agricultural antimicrobial use drives resistance transmission to humans, supporting One Health AMR policies and improved treatment strategies.
Funder: Canadian Institutes of Health Research
Due Dates: February 2, 2026: Pre-proposal submission deadline (Pre-Proposal to EUP OHAMR and Abbreviated Pre-Proposal to CIHR) | June 17, 2026: Full proposal submission deadline (Full Proposal to EUP OHAMR and Abbreviated Application to CIHR)
Funding Amounts: Up to CAN$200,000/year for 3 years (max CAN$600,000 total) for the Canadian component; only one Canadian team will be funded.
Summary: Supports research on the impact of veterinary and agricultural antimicrobial use on resistance transmission to humans, informing One Health AMR policies and treatment strategies.
Key Information: Projects must address human health and Topic 3; Canadian applicants must submit to both EUP OHAMR and CIHR.
This grant supports Canadian researchers participating in the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) Joint Transnational Call 2026, specifically focused on "Treatments and Adherence to Treatment Protocols." The call aims to advance innovative, cost-effective antimicrobial resistance (AMR) treatment options using a One Health approach that recognizes the interconnectedness of human, animal, plant, and environmental health. For CIHR funding, projects must address Topic 3: assessing the impact of antimicrobials used in veterinary and agricultural settings on the risk of AMR transmission to humans and the environment, with the goal of generating evidence to inform policies restricting certain antimicrobials for exclusive human use. Projects must include a human health research component and align with the Pan-Canadian Action Plan on AMR and CIHR-III's strategic priorities. Equity, diversity, inclusion, and Indigenous rights are emphasized.